Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Dr Neil Gross: Cemiplimab Has Great Potential in cSCC
December 5th 2022From comparing outcomes, it is known that cemiplimab has the potential to improve responses among patients who have cutaneous squamous cell carcinoma (cSCC), although many important questions remain, explained Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center
High-risk Disease, Novel Treatments, Health Care Equity Highlighted at SABCS
December 4th 2022The annual San Antonio Breast Cancer Symposium (SABCS) will once again take place in a hybrid fashion, with in-person attendees returning to the Henry B. Gonzales Convention Center to hear the latest clinical and basic research, as well as see several of their peers receive awards for their contributions to the space.
Dr Samyukta Mullangi: COVID-19 Has Spurred Us to Ask How We Can Innovate Care Delivery
December 1st 2022During an Institute for Value-Based Medicine® event held in New York City, Samyukta Mullangi, MD, MBA, fellow in medical oncology at Memorial Sloan Kettering Cancer Center, discussed how disruptions from the COVID-19 pandemic are ushering in health care delivery reform.
BMI Implicated in Glucocorticoid Insensitivity in CRSwNP
November 30th 2022The investigators of this study compared outcomes between patients who had eosinophilic or noneosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) by comparing the influence of body mass index (BMI) on each disease subtype.
Lack of Knowledge Continues to Influence Delayed Melanoma Diagnosis
November 29th 2022Malignant cutaneous melanoma outcomes were investigated as they relate to diagnosis delay and potential influence from socioeconomic and demographic factors in Brazil, where skin cancer diagnoses represent 30% of all cancer diagnoses.
Potential for ICI-Related Arrhythmias Necessitates Recognizing Risk Early
November 29th 2022Researchers pulled data from the FDA’s Adverse Event Reporting System to analyze cardiac arrhythmia–related outcomes among patients on a mono or combination regimen for cancer treatment that included immune checkpoint inhibitors (ICIs).
Risk of Subsequent Skin Cancer Seen Among Organ Transplant Recipients
November 24th 2022The study's goal was to clarify possible second and third skin cancer development patterns among organ transplant recipients who developed more than 1 instance of skin cancer and to better characterize this patient population by patient age and transplanted organ type.
Dr Tochi Okwuosa: There Is a Great Need for Better CVD Risk Prediction in Cardio-Oncology
November 19th 2022In an interview at this year’s American Heart Association Scientific Sessions meeting in Chicago, Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, discussed the importance of addressing cardiovascular disease (CVD) prevention in patients with cancer who are undergoing treatment.
Dr Emeline Aviki: Telehealth Allows Patients a Quick Return to Daily Life
November 19th 2022There is a major role for telehealth in oncology care, not only for its convenience but also for giving clinicians the ability to scale nononcologic visits, explained Emeline Aviki, MD, MBA, FACOG, assistant attending gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and lead of the MSKCC Affordability Working Group.
Sacubitril/Valsartan Linked to Improved Cardiac Autonomic Nervous System in HFrEF
November 15th 2022This international study, from investigators in Germany and Austria, looked at the effect sacubitril/valsartan can have among patients who have heart failure with reduced ejection fraction (HFrEF) and the impact on their cardiac autonomic nervous system.
Dr Stephen Schleicher: We Need to Focus More on Financial Toxicity
November 14th 2022Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
Dr Neil Gross on Potential Impact of Future Novel Treatments for cSCC
November 12th 2022Currently, there is no treatment approved for resectable cutaneous squamous cell carcinoma (cSCC), nor do we have biomarkers to predict treatment response, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center
Dr Amresh Raina Addresses Gender Differences in HF Presentation
November 12th 2022Disease symptomatology may be the same, but the presentation of heart failure (HF) and heart attacks differ between women and men, explained Amresh Raina, MD, of the Allegheny Health Network in Pittsburgh, Pennsylvania.
Comorbid Septic Shock, HFrEF Linked to Lack of Guideline-Recommended Treatment
November 10th 2022Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.
Nasal Cytology Produces Comparable Results to Surgery in CRSwNP
November 9th 2022The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could then facilitate patient selection for biological drug utilization via endotypization.
Dr Tochi Okwuosa: We Need More Data on Cardio-Toxicity From Radiation
November 8th 2022Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.
Dr Kausik Ray: ORION-3 Data Show Inclisiran Produces Durable Sustained LDL-C Reduction
November 7th 2022Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).